Articles tagged with Type 1 Diabetes
Researchers discovered a subpopulation of beta cells that resists immune attack and acquires stemness to persist despite immune attack. This finding may lead to therapies targeting these cells to restore insulin production in type 1 diabetic patients.
The American Diabetes Association has awarded a $1.625-million grant to develop an animal model studying the connection between gut bacteria and autoimmune attack in type 1 diabetes. The research aims to identify mechanisms that may contribute to the disease and potentially lead to treatments that prevent it.
Four NIH-funded research projects aim to test and refine fully automated artificial pancreas systems, replacing traditional methods for managing type 1 diabetes. The studies will evaluate safety, efficacy, user-friendliness, and cost, with the goal of bringing these life-changing devices to those who need them.
A long-term study found that continuous glucose monitoring significantly lowers blood sugar levels in persons with type 1 diabetes, reducing the risk of complications. The treatment also leads to increased well-being and improved treatment satisfaction.
A set of international guidelines helps individuals with type 1 diabetes exercise safely, reducing the risk of hypoglycemia and improving overall health. The guidelines provide recommendations for glucose targets, nutritional and insulin dose adjustments to prevent blood sugar fluctuations during exercise.
Two studies found that continuous glucose monitoring improved blood sugar levels and reduced hypoglycemia in type 1 diabetes patients using multiple daily insulin injections. The studies showed significant reductions in hemoglobin A1c levels and glycemic variability, with improved treatment satisfaction.
A new study reveals that individuals with Type 1 diabetes exhibit distinct gut inflammation and microbiome changes compared to those without diabetes or celiac disease. The research found specific genes associated with gut inflammation and unique combinations of gut bacteria in patients with Type 1 diabetes.
Researchers identified a molecular signaling pathway that promotes sensory neuron growth and prevents or reverses peripheral neuropathy in cell and rodent models of type 1 and 2 diabetes, chemotherapy-induced neuropathy, and HIV. Anti-muscarinic drugs already approved for other conditions may offer new treatment options.
A new study published in Diabetologia suggests that enterovirus infections are associated with the onset of autoimmunity in children who develop type 1 diabetes. The study found a higher incidence of enterovirus infections in children with T1D compared to control children, particularly those who developed islet autoantibodies.
The Human Pancreas Analysis Program (HPAP) aims to study diabetes and pancreatic islets with unparalleled resolution. The program will procure and phenotype pancreatic tissues from individuals with or at risk for Type 1 diabetes.
A study found that type 1 diabetes patients with elevated albumin in their urine had triple the risk of life-threatening kidney and cardiac disease compared to those with normal levels. Copeptin levels were significantly higher in these patients, suggesting a new potential target for therapies.
Researchers at Helmholtz Munich have discovered proteins in the blood that can predict incipient type 1 diabetes, even before symptoms appear. The study identified 41 peptides from 26 proteins that distinguish children with autoantibodies from those without, including proteins associated with lipid metabolism.
Researchers at Wayne State University are developing a new material formulation to resist foreign body reactions in implantable devices, such as insulin infusion pumps. This project aims to improve the long-term use of these devices by reducing the need for replacements.
Scientists at Helmholtz Zentrum München have discovered a mechanism used by the immune system to prepare for attacks on insulin-producing cells in the pancreas. The team identified a signaling pathway triggered by miRNA92a, which leads to an increase in immune cells that promote autoimmunity. Targeted intervention using antagomirs may ...
Researchers at the University of Cambridge have developed a new treatment for type 1 diabetes that targets the immune system's damage, aiming to reduce or eliminate daily insulin injections. The treatment uses aldesleukin, a drug that enhances regulatory T cells to prevent autoimmunity.
Aerobic exercise improves glycemic control and reduces insulin requirements in T1D patients. The study found that physically active patients had more responsible behavior in monitoring their glucose levels, suggesting an educational program addressing diet, insulin injecting monitoring, and exercise could be highly advantageous.
A recent study found a connection between follicular T helper cells and the development of type 1 diabetes. The cells were increased in frequency close to disease onset, particularly in children with multiple autoantibodies.
A recent expert review from the International Osteoporosis Foundation confirms that both type 1 and type 2 diabetes increase the risk of bone fragility. The mechanisms behind this include hyperglycemia, oxidative stress, and microvascular complications, which alter bone turnover and material properties.
Teresa Mastracci, a Senior Scientist at IBRI, has received a $750,000 JDRF Career Development Award to investigate polyamine and hypusine biosynthesis in reversing type 1 diabetes. Her research aims to identify new drugs that preserve or regenerate healthy beta cells, slowing or halting disease progression.
Teresa Mastracci, a researcher at the Indiana Biosciences Research Institute, has received a $750,000 JDRF grant to study polyamine and hypusine biosynthesis for reversing the progression of type 1 diabetes. The goal is to identify new drugs that preserve or regenerate healthy beta cells.
A clinical trial has shown that metformin can promote a patient's ability to repair their own damaged blood vessels by increasing vascular stem cells. This could lead to improved treatment options for Type 1 diabetes patients at risk of developing heart disease.
Research published in Nature Microbiology suggests that antibiotic treatment can alter the microbiome and increase the risk of developing type 1 diabetes. The study used NOD mice and found that short pulses of antibiotics increased disease incidence by 53% compared to control mice.
Researchers found that bilirubin supplementation significantly decreased islet cell death after isolation and nutrient deprivation. The study also showed that bilirubin suppressed the release of damage-associated molecular patterns (DAMPs), which are foreign cell-fighting immune cells.
A new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism found that a combination of three medications—dapagliflozin, liraglutide, and insulin—helped people with Type 1 diabetes improve blood sugar control and lose weight. The therapy also showed impressive improvements in blood glucose management.
A recent study found that breastfeeding for over three months postpartum alters maternal metabolism, producing lower concentrations of branched-chain amino acids and phospholipids. This change in metabolites is linked to reduced insulin resistance and a lower risk of developing type 2 diabetes.
Researchers found that patients with a rare autoimmune disorder produce antibodies that limit immune-related diseases, including type 1 diabetes. These autoantibodies target proteins such as interferons and interleukins, potentially inhibiting the development of type 1 diabetes.
Researchers tracked daily physical activity in 90 pre- to early-teenage children with type 1 diabetes and found improvements in blood vessel structure and reduced risk factors for heart disease. The study highlights the importance of physical activity for children with type 1 diabetes.
Researchers discovered that isoprene, a common natural chemical found in human breath, increases significantly at hypoglycemia levels. This finding may lead to the development of new tests for detecting hypoglycaemia and reducing its risk of life-threatening complications.
A recent study found that children with Juvenile Inflammatory Arthritis (JIA) have a significantly higher prevalence of Type 1 diabetes compared to the general population. The research, which included over 9,000 patients, suggests that understanding this link may lead to new treatments and preventative interventions for both diseases.
The Fr1da study has detected an early stage of type 1 diabetes in 105 out of 26,760 children aged two to five years. The children have not shown signs of metabolic imbalance, suggesting a potential breakthrough in preventive healthcare. Families are being offered comprehensive support and care.
A commentary published in Diabetes Technology & Therapeutics suggests that insulin pump therapy can lead to better blood glucose control and may be beneficial for all patients with type 1 diabetes. The author highlights the importance of pump technology, including sensor-controlled feedback and artificial pancreas systems.
A recent study published in The Journal of Clinical Investigation found that certain bacteria can activate killer T-cells, which destroy insulin-producing cells and lead to type 1 diabetes. This discovery sheds light on the potential external factors contributing to the disease's development.
Scientists at Washington University School of Medicine and Harvard University have produced insulin-secreting cells from stem cells derived from patients with type 1 diabetes. The new cells can produce insulin in response to glucose and may offer a potential cure for the disease.
Researchers found a direct correlation between increased life expectancy and the rise in type 1 diabetes cases globally. The study suggests that advances in medical care have reduced natural selection, allowing the underlying genetics of the disease to be passed from one generation to the next.
A study by Helmholtz Munich researchers found that viral respiratory tract disorders during the first six months of life significantly increase the risk of children developing type 1 diabetes. The infection localization and timing were key factors in determining the increased risk.
A study published in Diabetes Research and Clinical Practice reveals that children with type 1 diabetes are at risk of low vitamin D levels, affecting bone health, glucose metabolism, and immune function. The research emphasizes the importance of vitamin D screening for all children with type 1 diabetes.
The adAPT trial is a clinical study evaluating the effectiveness of metformin in preventing type 1 diabetes. Researchers aim to identify children at high risk and examine the impact of administering metformin on beta cell stress.
A clinical trial found that islet transplants effectively prevented severe hypoglycemic events and restored awareness in patients with Type 1 diabetes. The study also demonstrated excellent glycemic control, with nearly 88% of subjects remaining free from severe hypoglycemia at one year.
Researchers found that islet transplantation prevents severe hypoglycemic events in people who experienced episodes despite expert care. After one year, 88% of participants were free of severe hypoglycemic events and had restored hypoglycemic awareness.
Scientists have found that the RGS1 gene affects the frequency of T follicular helper cells, which are important for B cell production and seem to be crucial for the disease. The study suggests that while inhibiting RGS1 did not prevent autoimmune diabetes, it changes the way cells move within lymph nodes and spleen.
Two new studies found that life expectancy for people with type 1 diabetes has not decreased compared to the general population over the past few decades. The gap in life expectancy remained constant, with an estimated 12-13 years less life expectancy at birth for those with T1D.
Researchers at TSRI isolated a unique Treg cell from a mouse model of type 1 diabetes and discovered it originates in the thymus, giving rise to two functional states: an nTreg with active FoxP3 and a pre-nTreg without. This discovery opens new avenues for developing novel therapies to prevent autoimmune diseases.
A new study suggests that a combined vaccine therapy using live Salmonella is safe and effective in preventing diabetes in mice. The vaccine works by rebalancing the immune system and preventing the attack on insulin-producing cells. Researchers believe this targeted immunotherapy has great potential for treating type 1 diabetes.
Researchers have discovered a new potential therapy that can protect transplanted human pancreatic islets from dying. The study suggests that pretreating cells with a peptide hormone called cholecystokinin (CCK) may enhance the curative potential of islet transplant for Type 1 diabetes.
Research published in Diabetologia found that people with type 1 diabetes have a three-times increased risk of developing epilepsy later in life. Younger age and severe hypoglycemia are also identified as critical risk factors for brain abnormalities and the development of epilepsy.
Researchers aim to spare people with type 1 diabetes from lifelong insulin therapy by developing three-dimensional cellular structures of insulin-producing cells. The EU-funded project plans to work with pharmaceutical industry partners to mass-produce the cells for transplantation.
Scientists have developed novel insulin mimetopes that can induce regulatory T cells to produce tolerance against insulin, halting the development of type 1 diabetes in young mice. In a humanized mouse model, the new vaccine efficiently stimulates regulatory T cells, which can impede the immune system's attack on insulin-producing cells.
A multicentre study found type 1 diabetes associated with higher cancer incidence, especially for cancers of the stomach, liver, pancreas, endometrium, ovary, and kidney. Women with type 1 diabetes had a smaller but still significant increased risk compared to men.
Researchers have developed a novel therapeutic approach using nanomedicines called Navacims that can reprogram white blood cells to become regulatory cells capable of blunting autoimmune responses. The treatment has shown promising results in preclinical models of diabetes, multiple sclerosis, and rheumatoid arthritis.
Children diagnosed with type 1 diabetes before age seven develop a more aggressive form of the disease compared to teenagers. Researchers found that those diagnosed in childhood retain fewer insulin-producing beta cells than previously thought.
Researchers have identified a new drug target that can restore healthier lipid levels in people with type 1 diabetes. By blocking the growth hormone receptor, MIA-602 has been shown to reduce unhealthy lipids and improve vascular function.
Researchers found a link between pre-kallikrein levels and thickened blood vessels in type 1 diabetes patients. Elevated plasma PK levels are an independent risk factor for whole-body diabetic vascular disease, similar to high triglycerides or high blood pressure.
A study of over 99,000 children found that weight increase during the first year of life is associated with a higher risk of developing type 1 diabetes. The average change in weight from birth to 12 months was linked to an increased risk, while length gain showed no association.
A randomized trial found that metformin did not improve glycemic control after 6 months, despite reducing weight gain and insulin doses. The study included 140 adolescents with type 1 diabetes, aged 12-19 years, and was conducted at 26 pediatric endocrinology clinics.
A large-scale analysis of three diabetes registries found that insulin pump use is associated with lower mean HbA1c levels and better blood sugar control in children and adolescents with type 1 diabetes. Pump use was also more common among certain subgroups, such as girls and non-minority ethnic groups.
Researchers at Helmholtz Munich developed a method to predict the probability of developing postpartum diabetes after childbirth, using BMI and genetic predisposition as key factors. The test showed that women with low-risk scores had an 11% risk of developing diabetes within five years.
Researchers at Monash University discovered that regulatory T cells can function even when their receptors bind to MHC in a completely different orientation, challenging established views on the immune system. This finding opens up new avenues for investigating and potentially treating autoimmune diseases like type 1 diabetes.
Researchers have created a new investigational drug that traps IGFBP3, preventing gastrointestinal symptoms and restoring the intestine's mucosal lining structure. The drug may hold promise as a potential treatment for diabetic enteropathy, a common complication of type 1 diabetes.
Researchers discovered that excess IGFBP3 damages colonic stem cells, leading to intestinal lining damage and chronic gastrointestinal symptoms. A biopharmaceutical blocking circulating levels of the protein has shown promising results in reversing colon damage in diabetic mice.
Researchers create insulin-producing cells using adult tissue and transcription factors, offering a potential cure for type 1 diabetes. The cells can be transplanted into diabetic mice and may lead to clinical trials for human patients.